# Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

> **NCT00637377** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1240 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **BIOLOGICAL:** Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- **BIOLOGICAL:** Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- **BIOLOGICAL:** Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT00637377
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-09
- **Final completion:** 2011-08
- **Target enrollment:** 1240 (ACTUAL)
- **Last updated:** 2014-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637377, "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00637377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*